Fulcrum Therapeutics (FULC) Stock Forecast, Price Target & Predictions
FULC Stock Forecast
Fulcrum Therapeutics stock forecast is as follows: an average price target of $9.86 (represents a 210.06% upside from FULC’s last price of $3.18) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.
FULC Price Target
The average price target for Fulcrum Therapeutics (FULC) is $9.86 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $23.00 to $2.00. This represents a potential 210.06% upside from FULC's last price of $3.18.
FULC Analyst Ratings
According to 15 Wall Street analysts, Fulcrum Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FULC stock is 0 'Strong Buy' (0.00%), 7 'Buy' (46.67%), 7 'Hold' (46.67%), 1 'Sell' (6.67%), and 0 'Strong Sell' (0.00%).
Fulcrum Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Andrew Fein | H.C. Wainwright | $4.00 | $3.44 | 16.28% | 25.79% |
| Sep 12, 2024 | Gregory Renza | RBC Capital | $4.00 | $3.44 | 16.28% | 25.79% |
| Sep 12, 2024 | Dae Gon Ha downgraded Fulcrum Therapeutics | Stifel Nicolaus | $3.00 | $3.55 | -15.59% | -5.66% |
| Sep 12, 2024 | Tazeen Ahmad | Bank of America Securities | $2.00 | $3.44 | -41.86% | -37.11% |
| Sep 09, 2024 | Tazeen Ahmad | Bank of America Securities | $10.00 | $8.61 | 16.21% | 214.47% |
| Sep 03, 2024 | Gregory Renza | RBC Capital | $15.00 | $8.37 | 79.15% | 371.70% |
| May 20, 2024 | Kristen Kluska | Cantor Fitzgerald | $23.00 | $7.55 | 204.64% | 623.27% |
| May 13, 2024 | Corinne Jenkins | Goldman Sachs | $15.00 | $7.35 | 104.08% | 371.70% |
| May 13, 2024 | Dae Gon Ha | Stifel Nicolaus | $22.00 | $7.48 | 194.12% | 591.82% |
| Mar 13, 2024 | Gregory Renza | RBC Capital | $14.00 | $11.36 | 23.24% | 340.25% |
The latest Fulcrum Therapeutics stock forecast, released on Sep 13, 2024 by Andrew Fein from H.C. Wainwright, set a price target of $4.00, which represents a 16.28% increase from the stock price at the time of the forecast ($3.44), and a 25.79% increase from FULC last price ($3.18).
Fulcrum Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 6 | 6 | 10 |
| Avg Price Target | $6.33 | $6.33 | $11.20 |
| Last Closing Price | $3.18 | $3.18 | $3.18 |
| Upside/Downside | 99.06% | 99.06% | 252.20% |
In the current month, the average price target of Fulcrum Therapeutics stock is $6.33, according to 6 Wall Street analysts offering twelve months forecast. The average price target represents a 99.06% increase as opposed to Fulcrum Therapeutics's last price of $3.18. This month's average price target is down 0.00% compared to last quarter, and down -43.48% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Sep 13, 2024 | H.C. Wainwright | Hold | Neutral | Downgrade |
| Sep 12, 2024 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Sep 12, 2024 | Bank of America Securities | Neutral | Underperform | Downgrade |
| Sep 12, 2024 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| Sep 09, 2024 | Bank of America Securities | Underperform | Neutral | Upgrade |
| Sep 03, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 31, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 20, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| May 14, 2024 | Bank of America Securities | Underperform | Underperform | Hold |
Fulcrum Therapeutics's last stock rating was published by Leerink Partners on Sep 13, 2024. The company gave FULC a "Market Perform" rating, the same as its previous rate.
Fulcrum Therapeutics Financial Forecast
Fulcrum Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $871.00K | $759.00K | - | $295.00K | $685.00K | $1.18M | $1.88M | $2.59M | $5.06M | $4.93M | $4.38M | $4.79M | $4.22M | $1.85M | $750.00K |
| Avg Forecast | $73.29M | $74.37M | $75.46M | $76.57M | $142.86K | $112.50K | $14.82M | $416.67K | $552.72K | $1.05M | $1.12M | $1.07M | $1.89M | $2.54M | $2.96M | $3.94M | $2.68M | $2.25M | $2.40M | $2.14M | $1.31M | $687.50K | $694.44K |
| High Forecast | $73.29M | $74.37M | $75.46M | $76.57M | $142.86K | $112.50K | $14.82M | $416.67K | $680.27K | $1.05M | $1.12M | $1.07M | $1.89M | $2.54M | $2.96M | $3.94M | $2.68M | $2.25M | $2.40M | $2.14M | $1.31M | $687.50K | $833.33K |
| Low Forecast | $73.29M | $74.37M | $75.46M | $76.57M | $142.86K | $112.50K | $14.82M | $416.67K | $425.17K | $1.05M | $1.12M | $1.07M | $1.89M | $2.54M | $2.96M | $3.94M | $2.68M | $2.25M | $2.40M | $2.14M | $1.31M | $687.50K | $555.55K |
| # Analysts | 4 | 3 | 4 | 3 | 8 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 9 | 9 | 13 | 9 | 9 | 15 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | 1.58% | 0.72% | - | 0.28% | 0.36% | 0.47% | 0.63% | 0.66% | 1.89% | 2.19% | 1.83% | 2.24% | 3.23% | 2.69% | 1.08% |
Fulcrum Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $416.67K, with a low forecast of $416.67K, and a high forecast of $416.67K. FULC's average Quarter revenue forecast represents a -52.16% decrease compared to the company's last Quarter revenue of $871.00K (Dec 23).
Fulcrum Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 8 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 9 | 9 | 13 | 9 | 9 | 15 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | $-27.48M | $-27.44M | - | $-27.94M | $-28.05M | $-22.81M | $-33.56M | $-25.46M | $-22.86M | $-20.10M | $-18.98M | $-16.40M | $-16.99M | $-18.41M | $-17.91M |
| Avg Forecast | $-43.98M | $-44.62M | $-45.28M | $-45.94M | $-85.71K | $-67.50K | $-8.89M | $-250.00K | $-331.63K | $-631.28K | $-669.35K | $-640.23K | $-1.13M | $-24.52M | $-1.78M | $-24.99M | $-1.61M | $-1.35M | $-1.44M | $-19.38M | $-783.92K | $-412.50K | $-16.48M |
| High Forecast | $-43.98M | $-44.62M | $-45.28M | $-45.94M | $-85.71K | $-67.50K | $-8.89M | $-250.00K | $-255.10K | $-631.28K | $-669.35K | $-640.23K | $-1.13M | $-19.62M | $-1.78M | $-19.99M | $-1.61M | $-1.35M | $-1.44M | $-15.50M | $-783.92K | $-412.50K | $-13.18M |
| Low Forecast | $-43.98M | $-44.62M | $-45.28M | $-45.94M | $-85.71K | $-67.50K | $-8.89M | $-250.00K | $-408.16K | $-631.28K | $-669.35K | $-640.23K | $-1.13M | $-29.43M | $-1.78M | $-29.99M | $-1.61M | $-1.35M | $-1.44M | $-23.25M | $-783.92K | $-412.50K | $-19.78M |
| Surprise % | - | - | - | - | - | - | - | - | 82.88% | 43.47% | - | 43.64% | 24.73% | 0.93% | 18.87% | 1.02% | 14.22% | 14.88% | 13.21% | 0.85% | 21.67% | 44.63% | 1.09% |
undefined analysts predict FULC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fulcrum Therapeutics's previous annual EBITDA (undefined) of $NaN.
Fulcrum Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 8 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 9 | 9 | 13 | 9 | 9 | 15 | 18 |
| Net Income | - | - | - | - | - | - | - | - | $-24.76M | $-24.02M | - | $-21.62M | $-23.63M | $-24.05M | $-33.91M | $-25.86M | $-23.48M | $-20.72M | $-19.65M | $-17.00M | $-17.72M | $-18.96M | $-18.45M |
| Avg Forecast | $-24.80M | $-24.96M | $-24.54M | $-24.54M | $-21.46M | $-26.21M | $-26.20M | $-27.82M | $-27.07M | $-28.02M | $-28.86M | $-29.45M | $-31.15M | $-25.28M | $-42.01M | $-25.52M | $-46.26M | $-41.15M | $-41.49M | $-20.09M | $-46.10M | $-41.97M | $-16.98M |
| High Forecast | $-24.80M | $-24.96M | $-24.54M | $-24.54M | $-21.46M | $-24.25M | $-26.20M | $-27.82M | $-23.99M | $-28.02M | $-28.86M | $-29.45M | $-31.15M | $-20.22M | $-42.01M | $-20.41M | $-46.26M | $-41.15M | $-41.49M | $-16.07M | $-46.10M | $-41.97M | $-13.58M |
| Low Forecast | $-24.80M | $-24.96M | $-24.54M | $-24.54M | $-21.46M | $-28.83M | $-26.20M | $-27.82M | $-30.76M | $-28.02M | $-28.86M | $-29.45M | $-31.15M | $-30.34M | $-42.01M | $-30.62M | $-46.26M | $-41.15M | $-41.49M | $-24.11M | $-46.10M | $-41.97M | $-20.37M |
| Surprise % | - | - | - | - | - | - | - | - | 0.91% | 0.86% | - | 0.73% | 0.76% | 0.95% | 0.81% | 1.01% | 0.51% | 0.50% | 0.47% | 0.85% | 0.38% | 0.45% | 1.09% |
Fulcrum Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FULC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Fulcrum Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 8 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 9 | 9 | 13 | 9 | 9 | 15 | 18 |
| SG&A | - | - | - | - | - | - | - | - | $9.86M | $9.96M | - | $11.52M | $10.13M | $9.71M | $11.10M | $10.76M | $9.71M | $8.63M | $6.68M | $5.50M | $5.87M | $5.31M | $5.06M |
| Avg Forecast | $376.32M | $381.85M | $387.46M | $393.16M | $733.48K | $577.62K | $76.07M | $2.14M | $2.84M | $5.40M | $5.73M | $5.48M | $9.71M | $13.06M | $15.22M | $20.25M | $13.76M | $11.55M | $12.30M | $10.97M | $6.71M | $3.53M | $3.57M |
| High Forecast | $376.32M | $381.85M | $387.46M | $393.16M | $733.48K | $577.62K | $76.07M | $2.14M | $3.49M | $5.40M | $5.73M | $5.48M | $9.71M | $13.06M | $15.22M | $20.25M | $13.76M | $11.55M | $12.30M | $10.97M | $6.71M | $3.53M | $4.28M |
| Low Forecast | $376.32M | $381.85M | $387.46M | $393.16M | $733.48K | $577.62K | $76.07M | $2.14M | $2.18M | $5.40M | $5.73M | $5.48M | $9.71M | $13.06M | $15.22M | $20.25M | $13.76M | $11.55M | $12.30M | $10.97M | $6.71M | $3.53M | $2.85M |
| Surprise % | - | - | - | - | - | - | - | - | 3.48% | 1.84% | - | 2.10% | 1.04% | 0.74% | 0.73% | 0.53% | 0.71% | 0.75% | 0.54% | 0.50% | 0.87% | 1.50% | 1.42% |
Fulcrum Therapeutics's average Quarter SG&A projection for Mar 24 is $2.14M, based on 2 Wall Street analysts, with a range of $2.14M to $2.14M. The forecast indicates a -78.31% fall compared to FULC last annual SG&A of $9.86M (Dec 23).
Fulcrum Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 8 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 9 | 9 | 13 | 9 | 9 | 15 | 18 |
| EPS | - | - | - | - | - | - | - | - | $-0.40 | $-0.39 | - | $-0.36 | $-0.45 | $-0.52 | $-0.83 | $-0.64 | $-0.58 | $-0.57 | $-0.60 | $-0.54 | $-0.64 | $-0.70 | $-0.81 |
| Avg Forecast | $-0.39 | $-0.39 | $-0.39 | $-0.39 | $-0.34 | $-0.41 | $-0.41 | $-0.44 | $-0.43 | $-0.44 | $-0.45 | $-0.46 | $-0.49 | $-0.61 | $-0.66 | $-0.63 | $-0.73 | $-0.65 | $-0.65 | $-0.68 | $-0.72 | $-0.66 | $-0.75 |
| High Forecast | $-0.39 | $-0.39 | $-0.39 | $-0.39 | $-0.34 | $-0.38 | $-0.41 | $-0.44 | $-0.38 | $-0.44 | $-0.45 | $-0.46 | $-0.49 | $-0.61 | $-0.66 | $-0.63 | $-0.73 | $-0.65 | $-0.65 | $-0.68 | $-0.72 | $-0.66 | $-0.75 |
| Low Forecast | $-0.39 | $-0.39 | $-0.39 | $-0.39 | $-0.34 | $-0.45 | $-0.41 | $-0.44 | $-0.48 | $-0.44 | $-0.45 | $-0.46 | $-0.49 | $-0.61 | $-0.66 | $-0.63 | $-0.73 | $-0.65 | $-0.65 | $-0.68 | $-0.72 | $-0.66 | $-0.75 |
| Surprise % | - | - | - | - | - | - | - | - | 0.94% | 0.88% | - | 0.78% | 0.92% | 0.85% | 1.26% | 1.02% | 0.80% | 0.88% | 0.92% | 0.79% | 0.88% | 1.06% | 1.08% |
According to undefined Wall Street analysts, Fulcrum Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FULC previous annual EPS of $NaN (undefined).
Fulcrum Therapeutics Peer Comparison by Price Target
FULC Forecast FAQ
Is Fulcrum Therapeutics a good buy?
Yes, according to 15 Wall Street analysts, Fulcrum Therapeutics (FULC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 46.67% of FULC's total ratings.
What is FULC's price target?
Fulcrum Therapeutics (FULC) average price target is $9.86 with a range of $2 to $23, implying a 210.06% from its last price of $3.18. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Fulcrum Therapeutics stock go up soon?
According to Wall Street analysts' prediction for FULC stock, the company can go up by 210.06% (from the last price of $3.18 to the average price target of $9.86), up by 623.27% based on the highest stock price target, and down by -37.11% based on the lowest stock price target.
Can Fulcrum Therapeutics stock reach $5?
FULC's average twelve months analyst stock price target of $9.86 supports the claim that Fulcrum Therapeutics can reach $5 in the near future.
What is Fulcrum Therapeutics's current price target trend?
6 Wall Street analysts forecast a $6.33 price target for Fulcrum Therapeutics (FULC) this month, up 99.06% from its last price of $3.18. Compared to the last 3 and 12 months, the average price target increased by 99.06% and increased by 252.20%, respectively.
What are Fulcrum Therapeutics's analysts' financial forecasts?
Fulcrum Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $15.49M (high $15.49M, low $15.49M), average EBITDA is $-9.293M (high $-9.293M, low $-9.293M), average net income is $-102M (high $-99.723M, low $-104M), average SG&A $79.52M (high $79.52M, low $79.52M), and average EPS is $-1.599 (high $-1.568, low $-1.64). FULC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $299.7M (high $299.7M, low $299.7M), average EBITDA is $-180M (high $-180M, low $-180M), average net income is $-98.846M (high $-98.846M, low $-98.846M), average SG&A $1.54B (high $1.54B, low $1.54B), and average EPS is $-1.554 (high $-1.554, low $-1.554).
Did the FULC's actual financial results beat the analysts' financial forecasts?
Based on Fulcrum Therapeutics's last annual report (Dec 2023), the company's revenue was $2.8M, which missed the average analysts forecast of $3.79M by -25.94%. Apple's EBITDA was $-111M, beating the average prediction of $-2.272M by 4769.74%. The company's net income was $-97.335M, missing the average estimation of $-113M by -14.16%. Apple's SG&A was $41.67M, beating the average forecast of $19.45M by 114.27%. Lastly, the company's EPS was $-1.59, missing the average prediction of $-1.783 by -10.84%. In terms of the last quarterly report (Dec 2023), Fulcrum Therapeutics's revenue was $871K, beating the average analysts' forecast of $552.72K by 57.58%. The company's EBITDA was $-27.484M, beating the average prediction of $-332K by 8187.55%. Fulcrum Therapeutics's net income was $-24.756M, missing the average estimation of $-27.07M by -8.55%. The company's SG&A was $9.86M, beating the average forecast of $2.84M by 247.59%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.426 by -6.04%